GlassScriptPhysician profile
Thomas John Gianis
NPI 1467895375
$23,512.13
in general payments reported to CMS, 2019-2025
27 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2021: $906 · 2022: $1,086 · 2023: $15K · 2024: $3,501 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $17K · Food and Beverage: $3,551 · Travel and Lodging: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $16,875.00 |
| Food and Beverage | $3,550.51 |
| Travel and Lodging | $660.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $16,973.78 | 2022-2024 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Bard Peripheral Vascular, INC. | $1,258.26 | 2021-2025 | Lutonix Drug Coated Balloon, Rotarexs 6 F X 135 Cm, Venovo |
| Philips North America LLC | $1,111.85 | 2021-2025 | IV Other, Igt Devices Undivided, (Dd1) Duo Hybrid |
| Endologix LLC | $605.34 | 2022-2023 | Afx2 Bifurcated Endograft System, Alto Abdominal Stent Graft System |
| Medtronic Vascular, INC. | $433.75 | 2019 | |
| W. L. Gore & Associates, INC. | $408.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $394.08 | 2021-2024 | Xarelto |
| Tactile Systems Technology INC | $311.53 | 2022-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Shockwave Medical, INC | $308.12 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bsn Medical INC | $270.14 | 2023 | |
| Medtronic, INC. | $210.03 | 2022-2024 | Venaseal |
| Cook Medical LLC | $209.46 | 2021-2022 | |
| Kerecis Limited | $166.95 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Silk Road Medical, INC. | $139.75 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $137.20 | 2024 | Cios Alpha, Cios Spin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $86.33 | 2022 | |
| Bolton Medical INC | $70.77 | 2021-2022 | |
| Innovation Technologies INC | $67.39 | 2024 | Irrisept |
| Resmed Corp | $63.41 | 2023 | |
| Cordis US Corp. | $49.97 | 2025 | Mynx Control |
| Becton, Dickinson and Company | $48.12 | 2025 | Rotarexs 6 F X 135 Cm, Lifestent Solo Vascular Stent |
| Boston Scientific Corporation | $46.48 | 2024 | Varithena Administration Pack |
| Biotissue Holdings INC. | $42.16 | 2022 | |
| Biotronik INC. | $37.21 | 2025 | Pulsar-18 T3 |
| Surmodics, INC. | $26.14 | 2022 | |
| Cashflow Solutions, LLC | $21.91 | 2022-2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Convatec INC. | $13.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gianis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.